SCHEMBL2459367

SCHEMBL2459367

CC(C)(C)OC(=O)N1CCC[C@H](CNc2nc(Cl)ncc2Br)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 1/20 0.52
ACKR3 P25106 1/20 0.49
IDO1 P14902 2/20 0.48
TDO2 P48775 1/20 0.48
MERTK Q12866 1/20 0.45
HTR6 P50406 5/20 0.43
BCHE P06276 2/20 0.43
CYP2C9 P11712 1/20 0.43
CCNT1 O60563 1/20 0.43
CDK9 P50750 1/20 0.43
KDM1A O60341 1/20 0.43
GLS O94925 1/20 0.42
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
SCN9A Q15858 1/20 0.41
BACE1 P56817 2/20 0.41
CTSD P07339 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459363 1.00 IRAK1 (0.52) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL2463486 0.94 IDO1 (0.54) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL2460443 0.94 IDO1 (0.54) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL2460448 0.94 IDO1 (0.54) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL16336888 0.90 IRAK1 (0.53) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL16337471 0.90 IRAK1 (0.53) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL15055944 0.90 IRAK1 (0.53) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL2126475 0.90 IRAK1 (0.53) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL2126478 0.90 IRAK1 (0.53) IRAK1ACKR3IDO1TDO2MERTK
SCHEMBL2464315 0.89 IRAK1 (0.52) IRAK1ACKR3IDO1TDO2MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 US disclosed
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 US disclosed
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 US disclosed
WO-2009124965-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS PRKCZ, PRKCQ, PRKCD IRAK1 1527/4885ACKR3 977/4885IDO1 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.